Skip to content
Review

[Dysregulated control of hematopoietic stem cells in myeloid malignancies].

2026 · [Rinsho ketsueki] The Japanese journal of clinical hematology · Vol 67 9, pp. 1061-1068 · 0 citations
Medicine

TL;DR

Recent advances in understanding dysregulated HSC control in the early stages of myeloid neoplasia are summarized, with particular emphasis on aging, inflammation, immune interactions, and crosstalk with the bone marrow niche.

View source

Similar papers

Review Open access Oct 2026

Malignant remodeling of the bone marrow microenvironment in acute myeloid leukemia: mechanisms and therapeutic implications

Acute myeloid leukemia (AML) is an aggressive clonal myeloid malignancy characterized by the expansion of differentiation-arrested blasts. Treatment resistance, measurable residual disease, and relapse remain major causes of treatment failure. Experimental and clinical evidence indicates that the bone marrow microenvir...

Wen-Hao Xu, Qing-Lian Han, Chang-Rong Sun et al. · 0 citations
Review Open access Nov 2026

Regulatory T cells in the bone marrow microenvironment: homeostatic crosstalk, disease remodeling, and therapeutic opportunities

Regulatory T cells (Tregs) help maintain immune balance in hematopoietic niches by interacting with the bone marrow microenvironment. Under normal conditions, surrounding cells send signals that affect Treg movement, their length of stay in the bone marrow, their number and activity. In turn, Tregs affect hematopoietic...

Jia Hua Cheng, Qian Wang, Zhi-Feng Gu et al. · 0 citations
Review Open access Oct 2026

Dysregulation of the Bone Marrow Immune Microenvironment and Clinical Outcomes in Multiple Myeloma

The mechanisms underlying immune dysregulation in MM are discussed, recent discoveries regarding immune remodeling associated with clinical outcomes are summarized, and the translational implications of immune-based biomarkers and therapeutic strategies are explored.

Maria P. Ghirardi, Patrícia Brandalise, M. Berraondo et al. · 0 citations
Sep 2026

Multipotent Progenitor-3 Cells Are Reprogrammed by Bone-derived DKK1 to Drive Myelopoiesis in Breast Cancer.

The expansion of immunosuppressive myeloid cells drives tumor progression, yet clinical strategies aimed at depleting these populations have shown limited effects and high toxicity. Because myeloid cells arise from hematopoietic progenitors, we asked whether solid tumors durably reprogram hematopoietic stem and progeni...

Emily Eul, Giulia Furesi, Wen-Tao Han et al. · 0 citations
Review Open access Nov 2026

Beyond Clonal Hematopoiesis: Somatic Hematopoietic Mutations as Drivers of Cardiovascular Disease and Targets for Precision Therapy

Somatic hematopoietic mutations, particularly clonal hematopoiesis of indeterminate potential (CHIP), represent an emerging link between aging, inflammation and cardiovascular disease beyond their established relevance in hematology. This narrative review examines how acquired mutations in hematopoietic stem and progen...

M. Boz, Ivana Krajina, Z. Lewandowska et al. · 0 citations
Open access Sep 2026

Prefibrotic bone marrow microenvironment is a hallmark of clonal hematopoiesis

F fibro-inflammatory BM remodeling is established as a defining feature of clonal hematopoiesis of indeterminate potential, linking it to prefibrotic stromal changes and niche reorganization that may facilitate progression to overt malignancy.

Alicia G. Aguilar-Navarro, Gibran Edun, M. Gower et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.